当前位置:首页 >财报库 > 报告详情

Heart Test Laboratories, Inc(HSCS, HSCSW)美股招股说明书 S-1 (2024-03-05首版)(英文版)(72页).pdf

上传人: 1539****815 编号:896253 2024-03-05 72页 1.40MB

1、S-1 1 ea0200010-01.htm REGISTRATION STATEMENTAs filed with the Securities and Exchange Commission on March 5,2024.Registration No.333-_UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,DC 20549_FORM S-1REGISTRATION STATEMENTUnderTHE SECURITIES ACT OF 1933_Heart Test Laboratories,Inc.(Exact n

2、ame of registrant as specified in its charter)_Texas33451026-1344466(State or otherjurisdiction ofincorporation ororganization)(Primary StandardIndustrialClassification CodeNumber)(I.R.S.EmployerIdentification Number)550 Reserve St,Suite 360Southlake,Texas 76092682-237-7781(Address,includingzipcode,

3、andtelephonenumber,includingareacode,ofregistrantsproffices)_Danielle Watson550 Reserve St,Suite 360Southlake,Texas 76092682-237-7781(Name,address,including zip code,and telephone number,including areacode,of agent for service)_Copies to:Jonathan ShechterSasha AblovatskiyFoley Shechter Ablovatskiy L

4、LP1180 Avenue of the Americas,8th FloorNewYork,NewYork 10036Tel:(212)335-0465_Approximate date of commencement of proposed sale to the public:As soon aspracticable after the effective date of this Registration Statement.If any of the securities being registered on this Form are to be offered on a de

5、layed orcontinuous basis pursuant to Rule 415 under the Securities Act of 1933,check the followingbox:If this Form is filed to register additional securities for an offering pursuant toRule462(b)under the Securities Act,please check the following box and list the Securities Actregistration statement

6、 number of the earlier effective registration statement for the sameoffering.If this Form is a post-effective amendment filed pursuant to Rule 462(c)under theSecurities Act,check the following box and list the Securities Act registration statement number ofthe earlier effective registration statemen

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
根据报告的内容,本文主要介绍了Heart Test Laboratories公司及其产品MyoVista。关键点如下: 1. 公司专注于应用AI技术扩展和改进心电图(ECG)的临床用途,首个产品候选MyoVista是一个集成了AI算法的12导联心电图设备,用于检测心脏功能障碍。 2. MyoVista尚未获得FDA批准,公司正在准备重新提交FDA申请,预计2024年获得批准。 3. 心脏病是导致死亡的主要原因,但大多数患者在出现症状前无法被诊断。MyoVista的目标是更早地检测心脏疾病。 4. MyoVista的市场机会包括人口老龄化、心电图市场增长、早期风险识别需求增加以及医疗保健提供者变化。 5. 公司计划通过MyoVista硬件销售、耗材销售和AI算法订阅获得收入。 6. 公司正在开发基于云的平台,提供各种AI心电图算法,并与Mount Sinai合作获得13种算法的许可。 7. 公司需要额外资金来支持MyoVista的上市和研发。
心脏疾病早期筛查新利器?" "AI-ECG技术,心脏健康守护神?" 如何革新心脏病诊断?"
客服
商务合作
小程序
服务号
折叠